Haemonetics Corp (NYSE:HAE) is gaining market share in the plasma segment, particularly in the US and Europe, through technology upgrades and new long-term agreements with BioLife and Grifols.

Haemonetics updated its hospital revenue guidance to 24% to 26% reported growth and 12% to 14% organic growth, driven by strong adoption of hemostasis cartridges and vascular closure devices.

Learn about Haemonetics Corporation's recent stock drop after missing Q3 revenue estimates and how the company is adjusting ...

JMP Securities lowered the firm’s price target on Haemonetics (HAE) to $100 from $125 and keeps an Outperform rating on the shares. Haemonetics ...

BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...

Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www ...

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite ...

StockNews.com upgraded shares of Haemonetics (NYSE:HAE – Free Report) from a hold rating to a buy rating in a report published on Friday. HAE has been the topic of a number of other reports. Bank of ...

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems ...

Haemonetics (($HAE)) has held its Q3 earnings call. Read on for the main highlights of the call. The latest earnings call from Haemonetics ...